AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
Rhea-AI Summary
AEON Biopharma (NYSE: AEON) received an additional NYSE American notice on March 31, 2026, citing noncompliance with Section 1003(a)(ii) after reporting a stockholders' deficit of approximately $55 million as of December 31, 2025.
The company remains listed and subject to an existing compliance Plan through August 3, 2026, and continues trading under the symbol AEON with a ".BC" noncompliance indicator.
Positive
- NYSE American accepted a compliance Plan granting a deadline of Aug 3, 2026
- Company remains listed and the stock continues trading under AEON
Negative
- Stockholders' deficit of approximately $55 million as of Dec 31, 2025
- Noncompliant with Section 1003(a)(ii) requiring at least $4.0 million
- Reported losses in 3 of 4 most recent fiscal years, triggering standards
News Market Reaction – AEON
In the Apr 6 session, AEON gained 2.39%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Earnings and program update | Neutral | -0.5% | Full-year 2025 results plus ABP-450 biosimilar and liquidity update. |
| Mar 25 | FDA feedback update | Positive | -3.8% | Constructive FDA BPD Type 2a feedback on analytical similarity strategy. |
| Mar 09 | CFO appointment | Positive | +7.5% | Appointment of experienced biotech CFO to support regulatory and financing plans. |
| Mar 05 | Scientific meeting abstract | Positive | +2.9% | Acceptance of AAN poster on ABP-450 and Botox analytical comparability. |
| Jan 21 | FDA meeting & approvals | Positive | -14.0% | BPD Type 2a FDA meeting and shareholder approval of November financing deals. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions, with some positive regulatory and analytic updates followed by share price declines, and leadership or presentation news more often met with gains.
Over the last few months AEON has focused on its ABP-450 biosimilar program and balance sheet. A Jan 21 BPD Type 2a FDA meeting and shareholder approvals were followed by a -13.97% move despite constructive developments. Subsequent FDA feedback and analytical data updates on Mar 25 and Mar 30 also saw modest declines. In contrast, leadership and scientific visibility events on Mar 5 and Mar 9 produced gains. Today’s listing-standard notice fits an ongoing theme of financial strain alongside scientific progress.
Key Terms
form 10-k regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that on March 31, 2026, it received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that, following its year-end financial results, the Company is not in compliance with an additional continued listing standard set forth in the NYSE American Company Guide (the “Company Guide”).
As previously disclosed, on February 3, 2025, the Company received a notice (the “Original Notice”) that it was not in compliance with Section 1003(a)(i) of the Company Guide, which requires stockholders’ equity of at least
The current Notice indicates that the Company is now also not in compliance with Section 1003(a)(ii) of the Company Guide, which requires stockholders’ equity of at least
This Notice reflects an expected progression of the Company’s previously disclosed compliance status following its 2025 year-end results and does not have an immediate impact on the Company’s current listing, Plan Period, or Plan to regain compliance. The Company’s common stock will continue to trade on NYSE American under the symbol “AEON,” subject to the Company’s compliance with other listing standards. The Company’s ticker will continue to carry a “.BC” indicator to denote that it is below compliance, and the Company will remain listed on NYSE American’s noncompliant issuers list.
The Company remains subject to the terms of the Original Notice and continues to execute against the NYSE American approved Plan to regain compliance with NYSE American continued listing standards within the Plan Period. If the Company does not regain compliance by August 3, 2026, or does not make progress consistent with the Plan during the Plan Period, NYSE American may initiate delisting proceedings. The Company has a right to appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.
The Notice does not affect the Company’s business operations or its reporting obligations with the U.S. Securities and Exchange Commission.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company seeking full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds
Forward-Looking Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against AEON or others; (ii) AEON’s future capital requirements; (iii) AEON’s ability to raise financing in the future; (iv) AEON’s ability to continue to meet continued stock exchange listing standards; (v) the possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors; (vi) the Company’s ability to comply with the Plan; and (vii) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the SEC, which are available on the SEC’s website at www.sec.gov.
Contacts
Investor Contact:
Laurence Watts
New Street Investor Relations
+1 619 916 7620
laurence@newstreetir.com
Source: AEON Biopharma
